Litigation Details for NOVO NORDISK INC. v. RIO BIOPHARMACEUTICALS, INC. (D.N.J. 2024)
✉ Email this page to a colleague
NOVO NORDISK INC. v. RIO BIOPHARMACEUTICALS, INC. (D.N.J. 2024)
| Docket | ⤷ Start Trial | Date Filed | 2024-02-05 |
| Court | District Court, D. New Jersey | Date Terminated | 2024-09-17 |
| Cause | 35:271 Patent Infringement | Assigned To | Renee Marie Bumb |
| Jury Demand | None | Referred To | Sharon A. King |
| Patents | 10,220,155; 10,357,616; 10,376,652; 11,097,063; 11,311,679; 8,114,833; 8,684,969; 8,920,383; 9,108,002; 9,132,239; 9,265,893; 9,457,154; 9,616,180; 9,687,611; 9,775,953; 9,861,757; RE46,363 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in NOVO NORDISK INC. v. RIO BIOPHARMACEUTICALS, INC.
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .
Details for NOVO NORDISK INC. v. RIO BIOPHARMACEUTICALS, INC. (D.N.J. 2024)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2024-02-05 | External link to document | |||
| 2024-02-05 | 24 | Joint Discovery Plan | ”), 10,220,155 (the “’155 patent”), 10,357,616 (the “’616 patent”), 10,376,652 (the “’652 patent”), 11,097,063…expiration of U.S. Patent Nos. 8,114,833 (the “’833 patent”) and 9,265,893 (the “’893 patent”) (collectively…expiration of the ’833 patent, 8,684,969 (the “’969 patent”), 8,920,383 (the “’383 patent”), 9,108,002 (the…the “’002 patent”), 9,132,239 (the “’239 patent”), 9,457,154 (the “’154 patent”), 9,616,180 (the “’180…180 patent”), 9,687,611 (the “’611 patent”), 9,775,953 (the “’953 patent”), 9,861,757 (the “’757 patent | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
